Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sieber, M.
Right arrow Articles by Diehl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sieber, M.
Right arrow Articles by Diehl, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:276-282, 2004
© 2004 European Society for Medical Oncology

Original Paper

Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial

Received 14 March 2003; revised 25 July 2003; accepted 4 September 2003

Background:

The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP (cyclophosphamide–vincristine–procarbazine–prednisone–doxorubicin–bleomycin–vinblastine–ifosfamide–methotrexate–etoposide) (CAI) with that of the standard regimen COPP/ABVD (COPP/ABV, dacarbacine) (CA) in the treatment of advanced-stage Hodgkin’s disease (HD).

Patients and methods:

Between January 1988 and January 1993, 588 eligible patients with HD in stages IIIB and IV were randomly assigned to a treatment or control group. The treatment group received four cycles of CAI over a complete cycle duration of 43 days. The control group received four cycles of CA over 57 days. Both groups then received consolidating radiotherapy.

Results:

Five hundred and eighty-four patients were suitable for arm comparison. Patients in each group were similar in age, sex, histological subtype and clinical risk factors. Complete remission rates, overall survival and freedom from treatment failure at 7 years were similar for the two groups: 77% versus 78%, 73% versus 73% and 54% versus 56% for CAI and CA, respectively. Differences in acute chemotherapy-related toxicity were significant, however. Prognostic factor analysis confirmed the relevance of the International Prognostic Index and revealed that stage IVB, low hemoglobin, low lymphocyte count, high age and male gender were associated with a poor prognosis

Conclusion:

The rapidly alternating hybrid CAI did not give superior results when compared with the standard regimen CA in advanced-stage HD.

M. Sieber*,§, H. Tesch, B. Pfistner, U. Rueffer, U. Paulus, R. Munker, R. Hermann, G. Doelken, P. Koch, J. Oertel, S. Roller, P. Worst, H. Bischof, A. Glunz, R. Greil, K. von Kalle, K. P. Schalk, D. Hasenclever, O. Brosteanu, E. Duehmke, A. Georgii, A. Engert, M. Loeffler and V. Diehl{ddagger}

Klinik I für Innere Medizin, University of Cologne, Cologne, Germany

Key words: advanced stage, chemotherapy, COPP/ABV/IMEP, Hodgkin’s disease, randomized clinical trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al.
MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors
Clin. Cancer Res., January 15, 2006; 12(2): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Carde
The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side?
J. Clin. Oncol., December 20, 2005; 23(36): 9058 - 9062.
[Full Text] [PDF]

Home page
 JCOHome page
B. Klimm, T. Reineke, H. Haverkamp, K. Behringer, H. T. Eich, A. Josting, B. Pfistner, V. Diehl, and A. Engert
Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group
J. Clin. Oncol., November 1, 2005; 23(31): 8003 - 8011.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.